Deborah Greengrass
Nurse Practitioner · West Orange, NJNPI 1134288491
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.4% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $699, 6.4 times the $109 reported in 2021.
Across 78 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$244
- Merck$193
- AstraZeneca$191
- Pfizer$120
- GSK$120
- Tempus AI, Inc$92
- plus $536 from 14 others
What the payments were for
- Food & beverage$1,39893%
- Education$987%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 9 | $244 |
| Merck | 10 | $193 |
| AstraZeneca | 11 | $191 |
| Pfizer | 7 | $120 |
| GSK | 7 | $120 |
| Tempus AI, Inc | 4 | $92 |
| Sumitomo Pharma America, Inc. | 6 | $91 |
| Caris MPI, Inc. | 3 | $73 |
| Myriad Genetic Laboratories, Inc. | 4 | $68 |
| AbbVie | 4 | $62 |
| Boston Scientific | 2 | $42 |
| Eisai Inc. | 2 | $37 |
| Millicent US Inc | 2 | $33 |
| Olympus America Inc. | 1 | $29 |
| Johnson & Johnson | 1 | $21 |
| Verastem, Inc. | 1 | $20 |
| Vertex | 1 | $18 |
| Avion Pharmaceuticals | 1 | $15 |
| Exeltis, USA Inc. | 1 | $15 |
| Immunogen, Inc. | 1 | $14 |
How this compares
$1,496 in reported general payments places this provider in the 85th percentile of 2,138 nurse practitioner providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 62 | $4,011 |
| Norethindrone Acetate | 13 | $759 |
| Clobetasol Propionate | 14 | $534 |
| Letrozole | 30 | $520 |
| Triamcinolone Acetonide | 61 | $311 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 15 | $138 |
| Nystatin | 14 | $120 |
| Fluconazole | 17 | $94 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in West Orange
- Nancy BonnetMorristown$407K
- Vanessa CoppolaCloster$205K
- Olufunmilayo IloriUnion$133K
- Janice BeitzHaddon Heights$75K
- Adewale AdefowojuUnion$70K
- Sophia KimEnglewood$70K
- Elizabeth FletcherCamden$62K
- Lannae EwingLinwood$39K
- Beth SavageNew Brunswick$34K
- Tina OcchiutoMorristown$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.